Key result
Rofecoxib showed an early increase in thromboembolic risk (diverging after 8 months), whereas the dose risk diverged only after 36 months, indicating dose-dependent periods of effect.
Why the study?
The period of drug exposure does not necessarily correspond to the period during which an adverse effect is produced, prompting the exploration of the pharmacologically pertinent period of effect in light of rofecoxib.
Does the pharmacologically pertinent period of effect (PPPE) for thromboembolic events differ between 25 mg and 50 mg doses of rofecoxib?
Does the pharmacologically pertinent period of effect (PPPE) for thromboembolic events differ between 25 mg and 50 mg doses of rofecoxib?
Answers are grounded in this paper and cite their sources.
The concept of Pharmacologically Pertinent Period of Effect (PPPE) highlights that the time window for adverse drug effects, such as rofecoxib-induced thromboembolic events, can vary significantly by dose.
BACKGROUND: The period of time during which a patient is exposed to a drug does not necessarily correspond to the period during which the drug produces the adverse effect under consideration. We propose the term Pharmacologically pertinent period of effect (PPPE) to address this time window. We explored the PPPE in light of the rofecoxib saga. METHODS: We identified the observational database studies of rofecoxib at doses 25 and 50 mg daily and thromboembolic events. We also obtained the Kaplan-Meier curves of Vioxx Gastrointestinal Outcomes Research trial (VIGOR) and Adenomatous Polyp Prevention on Vioxx (APPROVE) trials. RESULTS: We found seven observational studies with nine analyses. All the studies only looked at current exposure. At the dose of 25 mg, only three of nine analyses were barely statistically significant. At the dose of 50 mg, the risk ratios were much higher. The visual inspection of the Kaplan-Meier curves shows that in the APPROVE trial (25 mg), the placebo and rofecoxib curves start separating to become statistically significantly different only after 36 months. In contrast the VIGOR (50 mg), curves start separating very early and the divergence increases after 8 months. DISCUSSION: The 50 mg observational studies, looking at current exposure, correctively identified the almost immediate increase in risk evident in the VIGOR Kaplan-Meier curves. The absence of an immediate increase in risk shown by the APPROVE trial was also correctively identified by most observational 25 mg studies. To our knowledge no observational study was done on the long-term cardiac toxicity of the 25-mg dose. It would thus appear that the two doses of rofecoxib have different PPPEs.
No takes yet. Share an insight, caveat, or question.
Suissa et al. (2019) conducted a review in Thromboembolic events. Rofecoxib vs. Placebo was evaluated on Thromboembolic events. Rofecoxib showed an early increase in thromboembolic risk (diverging after 8 months), whereas the dose risk diverged only after 36 months, indicating dose-dependent periods of effect.
Synapse has enriched 10 related papers. Consider them for comparative context: